<DOC>
	<DOCNO>NCT00697242</DOCNO>
	<brief_summary>In present study immunogenicity , reactogenicity safety recombinant hepatitis B vaccine without MPL evaluate old healthy subject</brief_summary>
	<brief_title>Comparison Immuno , Reacto Safety Recombinant Hepatitis B Vaccine With Without MPL Healthy Older Adults</brief_title>
	<detailed_description>At time conduct study , sponsor GlaxoSmithKline know former name SmithKline Beecham</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female subject 50 70 year old . Written inform consent obtain subject . Good physical condition establish physical examination history take time entry Positive titres anti hepatitis antibody Any vaccination hepatitis B past . Any previous administration MPL Elevated serum liver enzymes two subsequent determination 14 day apart . History significant persisting hematologic , hepatic , renal , cardiac respiratory disease . Axillary temperature &gt; 37.5°C time injection . Any acute disease moment entry . Chronic alcohol consumption . Any treatment immunosuppressive immunostimulant therapy . Any chronic drug treatment , investigator 's opinion , preclude inclusion study . History allergic disease likely stimulate component vaccine . Administration vaccine ( ) immunoglobulin study period . Simultaneous participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Engerix™-B</keyword>
	<keyword>Recombinant Hepatitis B vaccine</keyword>
</DOC>